How long should children take montelukast?

Generally, the duration of montelukast treatment for children depends on the severity of their condition. For mild cases, treatment typically lasts 3–6 months; for severe cases, it may extend to 12–24 months.

Montelukast is commonly available as granules, tablets, and chewable tablets. As a leukotriene receptor antagonist, it is indicated for the prevention and long-term management of asthma in children—including prevention of both daytime and nighttime asthma symptoms. If a child experiences an acute asthma exacerbation, montelukast is generally continued after symptom control is achieved to consolidate therapeutic effects, typically for 3–6 months. Asthma is a chronic inflammatory airway disease, and montelukast helps reduce airway inflammation and lower airway hyperresponsiveness. Even after acute symptoms resolve, underlying airway inflammation may persist; therefore, continued therapy supports sustained disease control and reduces the frequency of asthma relapses.

Children with mild persistent asthma may require long-term montelukast therapy—often for 12–24 months—to prevent asthma attacks. The precise duration should be individualized based on factors including disease severity, frequency of exacerbations, and the child’s response to treatment. During therapy, physicians regularly assess asthma control—using tools such as pulmonary function tests and evaluation of symptom frequency—to guide adjustments in the treatment plan.

Parents should closely monitor their child’s physical condition, maintain a clean and hygienic environment, and ensure a light, balanced diet—measures that collectively support improved clinical outcomes.